{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:37:04Z","timestamp":1792597024378,"version":"4.5.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,12,13]],"date-time":"2019-12-13T00:00:00Z","timestamp":1576195200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002975","name":"Dainippon Sumitomo Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002975","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","prd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism & Related Disorders"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.parkreldis.2019.12.005","type":"journal-article","created":{"date-parts":[[2019,12,12]],"date-time":"2019-12-12T13:05:38Z","timestamp":1576155938000},"page":"91-97","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"C","title":["Effect of zonisamide on parkinsonism in patients with dementia with Lewy bodies: A phase 3 randomized clinical trial"],"prefix":"10.1016","volume":"76","author":[{"given":"Miho","family":"Murata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshinari","family":"Odawara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuko","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritsuko","family":"Kajiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisao","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Tagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Kosaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.parkreldis.2019.12.005_bib1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S1474-4422(03)00619-7","article-title":"Dementia with Lewy bodies","volume":"3","author":"McKeith","year":"2004","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.parkreldis.2019.12.005_bib2","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/ageing\/afi190","article-title":"A systematic review of prevalence and incidence studies of dementia with Lewy bodies","volume":"34","author":"Zaccai","year":"2005","journal-title":"Age Ageing"},{"key":"10.1016\/j.parkreldis.2019.12.005_bib3","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","article-title":"Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium","volume":"89","author":"McKeith","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2019.12.005_bib4","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.parkreldis.2010.06.004","article-title":"Levodopa response in dementia with Lewy bodies: a 1-year follow-up study","volume":"16","author":"Lucetti","year":"2010","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.parkreldis.2019.12.005_bib5","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1002\/mds.22322","article-title":"Effects of dopaminergic medications on psychosis and motor function in dementia with Lewy bodies","volume":"23","author":"Goldman","year":"2008","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2019.12.005_bib6","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/jnnp.2004.052332","article-title":"The role of levodopa in the management of dementia with Lewy bodies","volume":"76","author":"Molloy","year":"2005","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.parkreldis.2019.12.005_bib7","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1212\/01.wnl.0000250236.75053.16","article-title":"The Japan Zonisamide on PD Study Group, Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study","volume":"68","author":"Murata","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2019.12.005_bib8","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/ncn3.12026","article-title":"The Zonisamide PD Study Group, Randomized placebo-controlled trial of zonisamide in patients with Parkinson's disease","volume":"4","author":"Murata","year":"2016","journal-title":"Neurol. Clin. Neurosci."},{"key":"10.1016\/j.parkreldis.2019.12.005_bib9","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1002\/mds.26286","article-title":"The Japan Zonisamide on PD Study Group, Zonisamide improves wearing-off in Parkinson's disease: a randomized, double-blind study","volume":"30","author":"Murata","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2019.12.005_bib10","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0920-1211(95)00078-X","article-title":"Effects of zonisamide on dopaminergic system","volume":"22","author":"Okada","year":"1995","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.parkreldis.2019.12.005_bib11","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.expneurol.2009.11.018","article-title":"The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: clinical relevance","volume":"221","author":"Sonsalla","year":"2010","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.parkreldis.2019.12.005_bib12","doi-asserted-by":"crossref","first-page":"687","DOI":"10.2174\/1381612043453180","article-title":"Novel therapeutic effects of the anti-convulsant, zonisamide, on Parkinson's disease","volume":"10","author":"Murata","year":"2004","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.parkreldis.2019.12.005_bib13","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0920-1211(92)90087-A","article-title":"Zonisamide blocks T-type calcium channel in cultured neurons of rat cerebral cortex","volume":"12","author":"Suzuki","year":"1992","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.parkreldis.2019.12.005_bib14","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S1059-1311(96)80104-X","article-title":"Mechanisms of T-type calcium channel blockade by zonisamide","volume":"5","author":"Kito","year":"1996","journal-title":"Seizure"},{"key":"10.1016\/j.parkreldis.2019.12.005_bib15","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.neuropharm.2009.05.005","article-title":"Zonisamide enhances delta receptor-associated neurotransmitter release in striato-pallidal pathway","volume":"57","author":"Yamamura","year":"2009","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.parkreldis.2019.12.005_bib16","doi-asserted-by":"crossref","first-page":"e664","DOI":"10.1212\/WNL.0000000000005010","article-title":"Adjunct zonisamide to levodopa for DLB parkinsonism: a randomized, double-blind phase 2 study","volume":"90","author":"Murata","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2019.12.005_bib17","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1212\/01.wnl.0000187889.17253.b1","article-title":"Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium","volume":"65","author":"McKeith","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2019.12.005_bib18","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"\u201cMini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.parkreldis.2019.12.005_bib19","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1212\/WNL.44.12.2308","article-title":"The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia","volume":"44","author":"Cummings","year":"1994","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2019.12.005_bib20","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1002\/mds.23638","article-title":"Determination of minimal clinically important change in early and advanced Parkinson's disease","volume":"26","author":"Hauser","year":"2011","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2019.12.005_bib21","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/ana.23557","article-title":"Donepezil-DLB Study Investigators, Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled trial","volume":"72","author":"Mori","year":"2012","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.parkreldis.2019.12.005_bib22","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13195-014-0083-0","article-title":"Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled, confirmatory phase III trial","volume":"7","author":"Ikeda","year":"2015","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.parkreldis.2019.12.005_bib23","doi-asserted-by":"crossref","first-page":"787","DOI":"10.3233\/JAD-161109","article-title":"Long-term cognitive decline in dementia with Lewy bodies in a large multicenter, international cohort","volume":"57","author":"Kramberger","year":"2017","journal-title":"J. Alzheimer's Dis."},{"key":"10.1016\/j.parkreldis.2019.12.005_bib24","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-010357","article-title":"Cognitive decline in dementia with Lewy bodies: a 5-year prospective cohort study","volume":"6","author":"Rongve","year":"2016","journal-title":"BMJ Open"}],"container-title":["Parkinsonism & Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802019305243?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802019305243?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:19:49Z","timestamp":1761178789000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802019305243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":24,"alternative-id":["S1353802019305243"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2019.12.005","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of zonisamide on parkinsonism in patients with dementia with Lewy bodies: A phase 3 randomized clinical trial","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2019.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}